Opus Genetics, Inc.
LCA5
inherited retinal disease
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for LCA5 in inherited retinal disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Q4 2026LCA5 Phase 3 dosing initiation”